Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Allergy Therapeutics starts dosing for injected hay fever vaccine trial

Results are expected in the second half of 2018, following which Allergy will start work on the parameters for the Phase III trial
picture of needle
The hay-fever treatment is injected

Dosing has started in the Phase II study of Allergy Therapeutics plc’s (LON:AGL) injected, aluminium-free, hay fever vaccine. 

Results are expected in the second half of 2018, following which Allergy will expect to start work on the parameters for the Phase III trial.

READ: Allergy Therapeutics - strong financial showing, solid cash position, progress in the clinic

The year-long study, which will involve 440 patients across Germany, Austria and Poland, is designed to identify the optimal effective dose and will adopt the challenge testing method used recently in a birch pollen allergy study.

If approved, the product will be the first registered subcutaneous (injected under the skin) immunotherapy product in the US for allergy.

The US allergy immunotherapy market might be worth as much as US$2bn currently with grass vaccine sales of US$300-400mln per annum.

WATCH: Allergy Therapeutics preparing the ground for big opportunities in the US

Manuel Llobet, Allergy’s chief executive, said: "The start of treatment in this important Phase II trial marks an exciting and critical period of trials for the group's research and development pipeline.

"This trial aims to strengthen the Group's portfolio in Europe and the US and takes us another step closer to treating patients in the major US market."

View full AGY profile View Profile

Allergy Therapeutics plc Timeline

Related Articles

Proteomics International Laboratories: Access latest PPT from Proactive's CEO Sessions
April 13 2017
Richard Lipscombe talked revenue generation and growth path with investors.
blood_56ceb82789b61.jpg
December 15 2016
The company's nominated adviser said a partnership deal should be signed by the end of 2016
generic pill and bottle shot to denote Alliance's products
August 14 2017
The company has made the transition from a business capitalised at £90mln to company now worth around a quarter of a billion pounds - but has the market at large picked up on (and priced in) the transformation?

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use